致：香港交易及結算所有限公司 公司名稱: 麗珠醫藥集團股份有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 299,807,117 | RMB | | 1 | RMB | | 299,807,117 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 299,807,117 | RMB | | 1 | RMB | | 299,807,117 | | 2. 股份 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麗珠醫藥集團股份有限公司 呈交日期: 2025年10月6日 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 000513 | 說明 | | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 604,293,313 RMB | | 1 | RMB | | 604,293,313 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 604,293,313 RMB | | 1 | RMB | | 604,293,313 | 本月底法 ...

Group 1 - The company, Lijun Group, is committed to holding regular performance briefings to communicate its operational status to investors [1] - The communication channels between the company and investors are diverse and effective, ensuring ongoing dialogue [1] - The company plans to enhance its communication with investors through various means and will continue to prioritize information disclosure to convey its value to the market [1]

Core Viewpoint - Lijun Group has completed the enrollment phase of its phase III clinical trial for the weight loss indication of Semaglutide injection, which is designed in a head-to-head manner with the original product [1] Group 1 - The clinical trial is progressing smoothly with ongoing follow-up [1] - The company will continue to promote project progress through scientific and efficient research strategies [1] - Research results and subsequent application plans will be disclosed in a timely manner according to regulatory requirements [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年9月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price range is set between RMB 37.99 and RMB 38.46 per share [1] Financial Implications - The total expenditure for the buyback reflects the company's strategy to enhance shareholder value [1]

Group 1 - The company, Lijun Pharmaceutical (01513), announced a share buyback plan to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price is set between RMB 37.99 and RMB 38.46 per share [1]

Core Viewpoint - Lijun Pharmaceutical (01513.HK) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price per share ranges from RMB 37.99 to RMB 38.46 [1] Financial Implications - The total expenditure for the buyback represents a strategic investment in the company's own shares, potentially enhancing shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 2. 股份分類 | | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | | 2025年9月25日 | | 604,293,313 | | | 0 | | 604,2 ...

Group 1 - Company announced a share repurchase plan to buy back 129,300 A shares at a cost of RMB 5 million [1] - The repurchase price per share is set between RMB 38.49 and RMB 38.76 [1] - The repurchase is scheduled to take place on September 25, 2025 [1]